SCHEMBL22526666

SCHEMBL22526666

COC(=O)CCc1ccc(CCCOC[C@H](CCC(N)=O)NC(=O)OC(C)(C)C)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRB2 P07550 1/20 0.37
▸ ADRB1 P08588 1/20 0.37
▸ REN P00797 1/20 0.36
▸ PPARA Q07869 2/20 0.36
▸ HDAC3 O15379 1/20 0.36
▸ HDAC4 P56524 1/20 0.36
▸ HDAC1 Q13547 1/20 0.36
▸ HDAC7 Q8WUI4 1/20 0.36
▸ HDAC2 Q92769 1/20 0.36
▸ HDAC10 Q969S8 1/20 0.36
▸ HDAC11 Q96DB2 1/20 0.36
▸ HDAC8 Q9BY41 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ HDAC9 Q9UKV0 1/20 0.36
▸ HDAC5 Q9UQL6 1/20 0.36
▸ ATM Q13315 1/20 0.35
▸ CTSK P43235 2/20 0.35
▸ CTSS P25774 1/20 0.35
▸ CA2 P00918 4/20 0.35
▸ PPARG P37231 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22526938 0.91 ATM (0.40) RENPPARAATMCTSKCTSS
SCHEMBL25384288 0.87 PPARA (0.44) RENPPARAATMCTSKCTSS
SCHEMBL22526556 0.84 ADRB2 (0.38) ADRB2ADRB1RENPPARAHDAC3
SCHEMBL22526120 0.83 REN (0.40) RENATMCTSKCTSSCA2
SCHEMBL22527078 0.80 PLA2G2C (0.46) HDAC4HDAC1HDAC6CTSKCA2
SCHEMBL22527034 0.80 PPARA (0.47) PPARAATMCTSKCTSSPPARG
SCHEMBL26206085 0.80 ADRB2 (0.43) ADRB2ADRB1
SCHEMBL22526465 0.78 HDAC3 (0.40) ADRB2ADRB1RENHDAC3HDAC4
SCHEMBL22526680 0.77 PPARA (0.47) RENPPARAATMCTSKCTSS
SCHEMBL26237677 0.77 REN (0.40) RENPPARAHDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059221-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-02-20 — — US disclosed
US-12077555-B2 STAT degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-09-03 — — US disclosed
US-11746120-B2 Stat degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-09-05 — — US disclosed
US-11746120-B2 Stat degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-09-05 — — US disclosed
US-20230120381-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-20 — — US disclosed
US-20230084113-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-03-16 — — US disclosed
US-11485750-B1 STAT degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-11-01 — — US disclosed
WO-2020206424-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-10-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230084113-A1 STAT DEGRADERS AND USES THEREOF STAT4, STAT1, STAT3 ADRB2 4571/4885ADRB1 4560/4885REN 2661/4885
US-20230120381-A1 STAT DEGRADERS AND USES THEREOF STAT4, STAT1, STAT3 ADRB2 4571/4885ADRB1 4560/4885REN 2661/4885
US-12077555-B2 STAT degraders and uses thereof STAT4, STAT1, STAT3 ADRB2 4571/4885ADRB1 4560/4885REN 2661/4885
US-20250059221-A1 STAT DEGRADERS AND USES THEREOF STAT4, STAT1, STAT3 ADRB2 4571/4885ADRB1 4560/4885REN 2661/4885
US-11746120-B2 Stat degraders and uses thereof STAT4, STAT1, STAT3 ADRB2 4571/4885ADRB1 4560/4885REN 2661/4885
US-11485750-B1 STAT degraders and uses thereof STAT4, STAT1, STAT3 ADRB2 4571/4885ADRB1 4560/4885REN 2661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback